The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of pembrolizumab plus olaparib in the treatment of patients with advanced cholangiocarcinoma.
 
Aiwu Ruth He
Consulting or Advisory Role - Eisai; Genentech/Roche; Merck
Speakers' Bureau - Bristol-Myers Squibb; Eisai; Exelixis
Research Funding - Genentech; Merck
 
Benjamin Adam Weinberg
Honoraria - Onclive; Rafael Pharmaceuticals; Tempus
Consulting or Advisory Role - Bayer
Speakers' Bureau - Bayer; Lilly; Sirtex Medical; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Isofol Medical (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Caris Life Sciences
 
Marcus Smith Noel
Consulting or Advisory Role - Celgene; Taiho Pharmaceutical
Speakers' Bureau - Celgene; Taiho Pharmaceutical
 
Violeta P Milic
No Relationships to Disclose
 
Petra Prins
No Relationships to Disclose
 
Hongkun Wang
No Relationships to Disclose
 
Marion L. Hartley
No Relationships to Disclose
 
John Marshall
Employment - Caris Life Sciences; Indivumed
Honoraria - Amgen; Bayer/Onyx; Caris Life Sciences; Celgene; Genentech/Roche; Merck; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Bayer/Onyx; Caris Life Sciences; Celgene; Genentech/Roche; Taiho Pharmaceutical
Speakers' Bureau - Amgen; Bayer/Onyx; Celgene; Genentech/Roche; Merck; Taiho Pharmaceutical
Research Funding - Amgen (Inst); Bayer/Onyx (Inst); Boehringer Ingelheim (Inst); Genentech/Roche (Inst); MedImmune (Inst); Pfizer (Inst)